FIS1 and central nervous system cancer: Some examples include inhibiting PRMT1/ATF5 in neuroblastomas, increasing the level of ATF5 inhibition-related miRNAs in gliomas, targeting the Fis-1/ATF5 axis in metabolic diseases, or targeting ATF5 in diabetes.